Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Prevention of Meningococcal Infection”

47 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 47 results

Post-approval studies (Phase 4)Study completedNCT00316654
What this trial is testing

Persistence of Antibody Response to N. Meningitidis Group C in Children

Who this might be right for
Prevention of Meningococcal Infection
Novartis Vaccines 489
Large-scale testing (Phase 3)Study completedNCT00317109
What this trial is testing

Study to Asses DTPw-HBV/Hib at 15-18 Months (m) and Mencevax™ ACW at 24 to 30 m in Primed Subjects

Who this might be right for
Infections, Meningococcal
GlaxoSmithKline 168
Testing effectiveness (Phase 2)Study completedNCT00262028
What this trial is testing

Study of the Safety and Immune Response of a Meningococcal Vaccine Administered to Healthy Children

Who this might be right for
Prevention of Meningococcal Disease
Novartis Vaccines 910
Post-approval studies (Phase 4)Study completedNCT00310635
What this trial is testing

Safety, Tolerability and Immunogenicity of Meningococcal C Conjugate Vaccine to Children 32 to 40 Months of Age

Who this might be right for
Meningococcal Infection
Novartis 241
Post-approval studies (Phase 4)Not Yet RecruitingNCT07252804
What this trial is testing

Immunogenicity and Safety of MenB Vaccine in Pediatric Patients With Autoimmune Rheumatic Diseases

Who this might be right for
Autoimmune Rheumatologic Disease
University of Sao Paulo General Hospital 263
Testing effectiveness (Phase 2)Study completedNCT00433914
What this trial is testing

Safety, Tolerability and Immunogenicity of Two Different Formulations of Meningococcal B Recombinant Vaccine, When Administered to Healthy Infants

Who this might be right for
Meningococcal Disease
Novartis Vaccines 60
Large-scale testing (Phase 3)Study completedNCT00310674
What this trial is testing

Immunogenicity, Safety and Tolerability, of Chiron Meningococcal C Conjugate Vaccine Administered to Healthy Premature and Non Premature Children of 3 Months of Age

Who this might be right for
Prevention of Meningococcal Infection
Novartis 150
Large-scale testing (Phase 3)Study completedNCT00311415
What this trial is testing

Immunogenicity, Safety, Tolerability and Ability to Prime for Memory of Meningococcal C Conjugate Vaccine in Healthy Children

Who this might be right for
Prevention of Meningococcal Infection
Novartis Vaccines 257
Testing effectiveness (Phase 2)Study completedNCT00721396
What this trial is testing

Safety, Tolerability and Immunogenicity of Meningococcal B Recombinant Vaccine Administered With or Without Routine Infant Vaccinations to Healthy Infants According to Different Immunization Schedules

Who this might be right for
Meningococcal Infections
Novartis Vaccines 1,885
Large-scale testing (Phase 3)Study completedNCT01423084
What this trial is testing

Safety and Immunogenicity of Novartis Meningococcal B Vaccine Formulated With OMV Manufactured at Two Different Sites, in Healthy Adolescents Aged 11-17 Years

Who this might be right for
Meningococcal DiseaseMeningococcal Meningitis
Novartis 344
Large-scale testing (Phase 3)Study completedNCT00291343
What this trial is testing

Immune Response & Safety of GSK Biologicals' Mencevax™ ACWY in Subjects Primed in the DTPW-HBV=HIB-MENAC-TT-011 Study

Who this might be right for
Infections, Meningococcal
GlaxoSmithKline 296
Large-scale testing (Phase 3)Study completedNCT00136604
What this trial is testing

Response to GSK Biologicals' Tritanrix-HepB/Hib-MenAC Vacc (4th Dose) at 15-24m & Mencevax ACWY at 24-30m

Who this might be right for
Whole Cell PertussisHaemophilus Influenzae Type bHepatitis B+3 more
GlaxoSmithKline 617
Testing effectiveness (Phase 2)Study completedNCT01026974
What this trial is testing

Extension Study Evaluating Antibody Persistence and Safety, Tolerability and Immunogenicity of a Booster Dose of Novartis rMenB±OMV NZ Vaccine in Healthy UK Children Who Previously Received Three Doses of the Same Vaccine

Who this might be right for
Meningococcal Disease
Novartis Vaccines 120
Testing effectiveness (Phase 2)Study completedNCT01367158
What this trial is testing

Safety, Tolerability and Immunogenicity of a Third Dose of One of Four Different Formulations of rMenB + MenACWY Combination Vaccine in Adolescents Who Previously Received the Same Study Vaccines

Who this might be right for
Meningococcal DiseaseMeningococcal Meningitis
Novartis Vaccines 440
Large-scale testing (Phase 3)Study completedNCT01911221
What this trial is testing

A Phase 3b, Single-Center, Open-label Study to Assess the Immunogenicity and Safety of Novartis Meningococcal B Recombinant Vaccine When Administered at a 0, 2-Month Schedule in Healthy At-Risk Adults Aged 18 to 65 Years Inclusive.

Who this might be right for
Prevention of the Meningococcal Disease
Novartis Vaccines 13
Large-scale testing (Phase 3)Study completedNCT00847145
What this trial is testing

Extension Study of V72P13 to Evaluate the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered as a Booster or as a Two-dose Catch-up to Healthy Toddlers

Who this might be right for
Meningococcal Disease
Novartis Vaccines 2,249
Large-scale testing (Phase 3)Study completedNCT00657709
What this trial is testing

Immunogenicity, Safety and Lot to Lot Consistency of Novartis Meningococcal B Recombinant Vaccine When Administered With Routine Infant Vaccinations to Healthy Infants

Who this might be right for
Serogroup B Meningococcal Meningitis
Novartis Vaccines 3,630
Post-approval studies (Phase 4)WithdrawnNCT03431675
What this trial is testing

Ciprofloxacin for the Prevention of Meningococcal Meningitis 2018

Who this might be right for
Meningitis, Meningococcal
Epicentre
Large-scale testing (Phase 3)Study completedNCT01682876
What this trial is testing

Immunogenicity, Safety and 1 Year Persistence of Antibodies After Either One or Two Doses of Meningococcal ACWY Conjugate Vaccine in Healthy Children 2 Through 10 Years of Age.

Who this might be right for
Meningococcal DiseaseInfections, Meningococcal
GlaxoSmithKline 715
Post-approval studies (Phase 4)Study completedNCT00282295
What this trial is testing

US-licensed Combined Vaccine Against Tetanus & Diphtheria, Given With US-licensed Vaccine Against Meningococcal Disease

Who this might be right for
Acellular PertussisTetanusDiphtheria
GlaxoSmithKline 1,344
Load More Results